Safety and efficacy of EIK1003, a selective PARP1 inhibitor, as monotherapy in participants with advanced solid tumors

Category Primary study
Conference2025 ASCO Annual Meeting I
Year 2025
This article has no abstract
Epistemonikos ID: 3a9aad307bcc55ad0a2ea680edff0ee449e04a1b
First added on: Sep 03, 2025